



Myriad Genetics Corporate Presentation

11/12/14

Disclosure Statements

Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forward-looking statements.

Non-GAAP Financial Measures


In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. The Company's financial measures under GAAP include substantial one-time charges related to its acquisitions and ongoing amortization expense related to acquired intangible assets that will be recognized over the useful lives of the assets. Management believes that presentation of operating results that excludes these items provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. A reconciliation of the GAAP to non-GAAP financial guidance is provided below.

	Fiscal Year 2015
GAAP diluted net income per share	\$1.75 - \$1.85
Acquisition – amortization of intangible assets	\$0.15
Non-GAAP diluted net income per share	\$1.90 - \$2.00

Well-Positioned Industry Leader


Myriad Genetics is dedicated to saving lives and improving the quality of life of patients through the discovery and commercialization of novel, transformative diagnostic tests across major diseases

- Largest molecular diagnostic clinical laboratory in the world
- Global leader in hereditary cancer risk assessment
- Pioneer in personalized medicine and companion diagnostics
- Trailblazer in autoimmune disease management
- \$778 million in FY2014 revenues (27% growth over FY2013)



The Myriad Vision

**A TRUSTED ADVISOR ANSWERING
PATIENT'S MOST PRESSING CONCERNS**



Oncology

Preventive Care

Urology

Autoimmune

Dermatology

Neuroscience


Multiple Growth Opportunities

Business Strategy

Transition
Hereditary
Cancer
Market

Diversify
the
Portfolio


Expand
Global
Presence



Fuel Strong Long-Term Top Line Growth


Value of Identifying High Risk Patients

- Identifying hereditary disease saves lives
- Patients can take preventive measures to reduce risk of cancer
- Preventing cancer saves healthcare system money



myRisk Hereditary Cancer™

- 25 gene panel assesses cancer risk
- Over 50 million covered lives
- All genes are clinically actionable
- Identifies risks for eight cancers
- Finds 51% more people at risk for breast cancer than BRCA
- Building database on all 25 genes
- Test accuracy is 99.99%
- \$5 billion global market



Multiple Growth Opportunities

Business Strategy

Transition
Hereditary
Cancer
Market

Diversify
the
Portfolio

Expand
Global
Presence




Fuel Strong Long-Term Top Line Growth

4_{in}6 Pipeline Projects

	MYRIAD myRisk™ Hereditary Cancer	MYRIAD myPath™ Melanoma	MYRIAD myPlan™ Lung Cancer	MYRIAD myChoice™
	Risk?	Diagnosis?	Prognosis?	Therapy?
Oncology	✓ 4	1	✓ 1	6
Preventive Care	✓	1		
Urology	1	1	✓	1
Dermatology	✓ 1	✓	1	
Neuroscience		2		1
Autoimmune		1		✓ 2

 Currently Marketed
  Under Development

Myriad Historic Publication Record




Product Pipeline

Significant Revenue Growth Drivers

Near Term 1 year	Mid Term 2-3 years	Long Term 3 years +
<ul style="list-style-type: none">▪ myRisk HC▪ Prolaris▪ Vectra DA▪ EndoPredict▪ BRACAnalysis CDx▪ Tumor BRACAnalysis CDx	<ul style="list-style-type: none">▪ myPath Melanoma▪ myPlan Lung Cancer▪ myChoice HRD▪ myPlan Renal Cancer	<ul style="list-style-type: none">▪ myChoice HRD (PARP)▪ myPath BiPolar▪ myRisk Schizophrenia▪ Juvenile RA▪ Psoriatic Arthritis▪ Ankylosing Spondylitis

Future Global Market Opportunity



■ myRisk HC

■ myChoice HRD/BRACAnalysis CDx

■ Vectra DA

■ Prolaris


■ EndoPredict/myPlan Lung Cancer

■ myPath Melanoma

PROLARIS®

- 46 gene panel assesses aggressiveness of prostate cancer
- Most prostate cancer patients don't require surgery
- 85% to 90% have treatment with side effects
- Validated in seven peer reviewed publications with gold standard outcomes of survival and metastases
- Prolaris changed treatment decisions for up to 65% of patients
- \$2 billion global market
- Recently received draft LCD from Medicare covering the test for low risk patients

PROLARIS® Predicts Prostate Cancer Survival




* Data presented at ASCO 2014

myPath Melanoma™

- 23 gene panel for diagnosis of melanoma
- Misdiagnosis is leading cause of malpractice suits
- Accurately differentiates between melanoma and benign skin lesions
- Effective for all four major melanoma subtypes
- myPath changed treatment decisions for 35% of patients
- 14% of biopsies in U.S. are indeterminate every year
- \$1 billion global market

myPath Accurately Identifies Melanoma Skin Cancer



* Data presented at ASCO 2014

Vectra DA™

- 12 protein panel measures disease activity in RA patients
- 1.5 million adults with rheumatoid arthritis in U.S
- Predicts irreversible joint damage in RA patients
- Guides treatment decisions
- 2-6 tests needed each year for rest of patient's life
- myRA patient app facilitates patient monitoring
- \$3.0 billion global market



Clinical Features

59 years old
RA for 5 years
Seropositive
DAS28-CRP = 1.9 (low)

Current treatment

Stable MTX

22

LOW



Clinical Features

62 years old
RA for 4 years
Seropositive
DAS28-CRP = 1.7 (low)

Current treatment

Stable MTX

54


INCREASED

**Vectra DA
Score**

Endopredict™

- 8 gene panel guides chemotherapy for breast cancer patients
- 60% of patients treated will not benefit from chemotherapy
- Test performed on site in cancer center
- No confusing intermediate results
- 13 clinical studies published with over 2,200 patients
- 250,000 breast cancer candidates in Europe each year
- \$375 million European Market

EndoPredict Predicts Breast Cancer Survival




* Data Published in Annals of Oncology 2012

myPlan Lung Cancer™

- 31 gene panel guides lung cancer chemotherapy
- Accurately predicts risk of dying from lung cancer
- Benefits patients with Stage 1 or Stage 2 lung cancer
- Stronger predictor than tumor size or stage of disease
- 34,000 early stage lung cancer patients in the U.S. every year
- \$250 million global market

myPlan Predicts Lung Cancer Survival




* Validation of a Proliferation-based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma (Bueno)

Companion Diagnostic Portfolio

- Identify cancer patients with tumors that lack the ability to repair DNA
- Likely to respond to DNA damaging agents (PARP or platinum drugs)
- 2,000,000 patients per year (U.S. & Europe) potentially eligible

Ovarian Cancer Patients Testing Positive



- Journal of Clinical Oncology August 2010; British Journal of Cancer November, 2012


CDx Development Projects Underway

	BRACAnalysisCDx™	Tumor BRACAnalysisCDx™	MYRIAD myChoice™ HRD
PARP Inhibitors	<ul style="list-style-type: none"> Current indications in Phase 3 clinical trials: TNBC, Neoadjuvant TNBC, Metastatic TNBC, adjuvant TNBC, neoadjuvant ovarian, MetBC Her 2-/ER+ Current partners: ABBV, AZN, BMRN, Janssen (JNJ), TSRO, and other undisclosed partners 	<ul style="list-style-type: none"> Signed research collaboration with ABBV and TSRO Expect to announce Phase 3 clinical trials 	<ul style="list-style-type: none"> Signed research collaborations with TSRO and BMRN Expect to announce Phase 3 clinical trials
Platinum Therapies	<ul style="list-style-type: none"> TNBC Neoadjuvant 	NA	<ul style="list-style-type: none"> TNBC Neo & Met BC

BRACAnalysis CDx™

- Test predicts patient response to PARP inhibitors
- PDUFA date for olaparib is scheduled for January 3, 2015.
- All four PMA modules submitted; FDA facility inspection complete.
- In nine Phase 3 clinical studies
- Studying PARP inhibitor benefit in ovarian, breast, lung, prostate, gastric, and pancreatic cancers

BRCA Positive Patients Benefit from Olaparib




* Data presented at ASCO, 2013

Tumor BRACAnalysis CDx™

- Test predicts patient response to PARP inhibitors
- EMA CHMP label recommendation supports tumor testing; test launched in Europe
- Tumor testing finds up to 50% more responders than conventional germ line testing.
- Recently announced collaborations with Tesaro and AbbVie on Tumor BRACAnalysis CDx

Finds Up to 50% More Patients Who Will Respond




* Data presented at the European Society of Medical Oncology Meeting 2014

myChoice HRD™

- Test uses three technologies to predict patient response to:
 - Platinum Drugs
 - PARP inhibitor Drugs
- Current cancers being studied in clinical trials represent a 900,000 patient U.S. opportunity annually
- Only 30% of patients benefit from platinum drugs; high HRD patients have a 70% response rate
- Launch scheduled for 2H FY2015
- \$6 billion global market

myChoice HRD Predicts Chemotherapy Response



* Data presented at SABCS, 2012

Multiple Growth Opportunities

Business Strategy


**Transition
Hereditary
Cancer
Market**



**Diversify
the
Portfolio**



**Expand
Global
Presence**



Fuel Strong Long-Term Top Line Growth


International Operations

- 45 person European sales team
- Distributors in 80 countries
- Revenue up 109% in FY 2014
- Strong revenue growth from myRisk, Endopredict, BRACAnalysis, and Prolaris
- Launch of Vectra DA in 1H FY15
- Major opportunity with PARP inhibitors in European market
- \$8 billion European market




Delivering Strong Growth

Revenue



Adjusted EPS



Fiscal Year 2015 Guidance

Revenue Guidance (Millions of Dollars)

Total Revenue

800 - 820

Earnings Guidance (Dollars)

Adjusted Diluted EPS

1.90 - 2.00

Myriad Core Competencies

- **Pioneer in Molecular Diagnostics:**
 - 13 proprietary molecular diagnostic products on market
 - Commercial products in oncology, urology, rheumatology, dermatology, and women's healthcare
 - Expert in all three biomarker technologies (DNA, RNA, and protein)
 - Industry leading pipeline of 10 molecular diagnostic products
- **Trailblazer in Personalized Medicine:**
 - First test to assess prostate cancer survival
 - First test to assess rheumatoid arthritis disease activity
 - First FDA approved complex companion diagnostic
 - First companion diagnostic test to assess HRD